Reprint

Urological Cancer 2020

Edited by
August 2021
334 pages
  • ISBN978-3-0365-0270-0 (Hardback)
  • ISBN978-3-0365-0271-7 (PDF)

This book is a reprint of the Special Issue Urological Cancer 2020 that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

This Urological Cancer 2020 collection contains a set of multidisciplinary contributions to the extraordinary heterogeneity of tumor mechanisms, diagnostic approaches, and therapies of the renal, urinary tract, and prostate cancers, with the intention of offering to interested readers a representative snapshot of the status of urological research.

Format
  • Hardback
License
© by the authors
Keywords
renal cell carcinoma; iron; macrophages; chelation therapy; urothelial carcinoma; transcriptome; microtubule; MAP1B; prognosis; KLF5; androgen receptor; cell proliferation; tumorigenesis; prostate cancer; prostate cancer; precision medicine; whole genome sequencing; optical mapping; therapy; prostate carcinoma; prostate mpMRI; machine learning; artificial intelligence; deep learning; neural network; prostate cancer; angiogenesis; angiogenic growth factors; antiangiogenic therapy; renal tumors; prevention; α1-adrenoceptor antagonists; anoikis; vascularity; prostate cancer; research model; oncogenes; tumor suppressor genes; MR-guided; radiotherapy; MRgRT; stereotactic ablative radiotherapy; stereotactic ablative radiation therapy (SABR); renal cell cancer; RCC; online adaptive; [68Ga]Ga-PSMA PET/CT; prostate cancer; dual-time point imaging; delayed imaging; biphasic imaging; lesion positivity rate; CXCL9; PD1; PD-L1; stage T1 NMIBC; prognosis; prostatic neoplasms/mortality; prostatic neoplasms/epidemiology; SEER Program; bladder cancer; transurethral resection; en-bloc resection; CPT1A; prostate cancer; fatty acids; serine; androgen response; ROS; oxidative stress; prostate carcinoma; DONSON; Downstream Neighbor of SON; biomarker; metastatic spread; bladder cancer; diagnosis; differential diagnosis; prognosis; histopathology; immunohistochemistry; prostate cancer; stroma signature; patient-derived xenografts; n/a